復星醫藥(02196.HK)子公司擬與BioNTech設立合資公司 實現新冠疫苗產品本地化生產及商業化
格隆匯 5 月 9日丨復星醫藥(02196.HK)發佈公吿,2021年5月8日,復星醫藥產業與BioNTech訂立一份條款書,內容有關為新冠疫苗產品的本地化生產及商業化而擬設立一家合資公司,該合資公司由復星醫藥產業以及BioNTech分別持有50%股權。
根據該條款書,復星醫藥產業同意以現金及╱或有形、無形資產(包括廠房及生產設施等)向合資公司作價出資總額不超過1億美元,而BioNTech以其相關生產技術和專有技術許可等無形資產作價出資總額不超過1億美元。條款書具有法律約束力,雙方應按設立合資公司的要求採取任何行動以履行其項下義務,但條款書約定雙方應進一步就設立合資公司簽訂最終交易文件。
BioNTech系一間於德國註冊成立的公司,其主要致力於癌症、傳染病和其他嚴重疾病的治療和預防性免疫療法的研究和開發。BioNTech是業內領先的mRNA平台型生物技術公司之一,且已建立較大規模的生產製造設施。就合資公司新冠疫苗產品的具體生產和銷售計劃須待雙方進一步協商,並受到商業化生產上市的前提條件(包括但不限於取得相關許可及批准等)等諸多因素影響,以及就現有協議項下在該區域內的新冠疫苗產品的供貨安排或調整,尚待相關方進一步協商確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.